OVERVIEW

Migraine Headaches: Therapeutic Updates and Contemporary Management Strategies is organized by ScientiaCME.

Release Date: May 31, 2019
Expiration Date: May 31, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-19-020-H01-P. ACPE Accreditation effective 6/10/19, expires 6/10/21.

Description:
In this online CME self-learning program:
Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. The condition has been identified as one of the most common neurological disorders occurring in adult women (17%) approximately three times more than in men: in the U.S. 17.1% of women and 5.6% of men experience at least one migraine per year. It is one of the top five reasons for emergency department visits by patients ages 18 to 44.

A provider’s first priority when seeing a patient with headaches is to determine whether the patient is presenting with a primary headache disorder or a secondary headache disorder. Primary headache disorders include migraine headaches, tension-type headaches, and cluster headaches. Secondary headaches are those attributed to an underlying condition such as infection, trauma, vascular disorders, or structural lesions. They cost thousands of per patient per year and are the third leading cause of disability in the world.

Objectives:
By the end of the session the participant will be able to:
• Describe clinical features of migraines, the rationale for understanding migraine as a syndrome, and migraine neurochemistry (including calcitonin gene-related peptide, serotonin, etc.) such that that they inform pairing with treatment mechanisms
• Describe the characteristics of diagnosis of episodic and chronic migraines and the qualities embodied by patients suitable for prophylactic pharmacotherapy, and apply that knowledge to patient cases
• List present and emerging pharmacotherapeutic treatment options for both prophylactic and rescue therapies for migraine headaches and apply them to patient cases using evidence-based medicine
• Describe challenges to the successful management of migraine, including through a collaborative care, team-based approach between disciplines